|
Pembrolizumab in advanced endometrial cancer: Preliminary results from the phase Ib KEYNOTE-028 study. |
|
|
Consulting or Advisory Role - Alexion Pharmaceuticals; Amgen; Bristol-Myers Squibb |
Research Funding - ARMO BioSciences; AstraZeneca; Bristol-Myers Squibb; Merck |
|
|
Consulting or Advisory Role - Merck |
Research Funding - Merck (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Perthera |
Honoraria - Caris Life Sciences; Celgene; Sirtex Medical |
Consulting or Advisory Role - Caris Life Sciences; Celgene; Perthera; Sirtex Medical |
Research Funding - Celldex (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst) |
Travel, Accommodations, Expenses - Caris Life Sciences; Perthera; Sirtex Medical |
|
|
Honoraria - Genomic Health |
Speakers' Bureau - Genomic Health |
Research Funding - Celsion (Inst); Celsion (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Plexxikon (Inst) |
Travel, Accommodations, Expenses - Mylan; Nektar; Novartis; OBI Pharma; Roche/Genentech |
|
|
Consulting or Advisory Role - Amgen; Roche/Genentech |
Travel, Accommodations, Expenses - Amgen |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen/Dompé (Inst) |
Research Funding - Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); polynoma (Inst); Sanofi (Inst) |
Other Relationship - Amgen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
Honoraria - AstraZeneca/MedImmune; Merus; MSD Oncology; Pfizer; Roche/Genentech; Symphony Evolution |